Heald’s money-back guarantee boldly links business success to patient outcomes,” said Dr. Neal Patel, CIO at Vanderbilt ...

RxSight’s management is scheduled to present on Thursday, September 4, 2025, at 7:15 a.m. Pacific Time / 10:15 a.m. Eastern Time. A live and archived webcast of the presentation will be available at: ...

The Company intends to use the net proceeds from the initial public offering for furthering the development of its intranasal Epinephrine program, including, manufacturing scale-up and additional ...

Next-generation claudin 18.2 ISAC BDC-4182 now in Phase 1 dose-escalation study ; Cash balance of $48.5 million as of June 30, 2025 anticipated to fund key milestones through mid- ...

Second quarter 2025 revenue was $3.3 million, a 17% increase over the second quarter of 2024. New accounts grew 75% in the second quarter of 2025 over the comparable quarter in 2024. CapsoCam Plus® ...

BioStem Technologies, Inc. (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for ...

NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today ...

Submitting the Company’s Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration in the fourth quarter of 2025, to initiate a U.S. long-term, multicenter Pilot Study of the ...

On June 12, 2025, the Company was honored with the prestigious 2025 "Disinfection and Decontamination Products Company of the Year" award by MedTech Outlook. This recognition highlights TOMI’s ...

Investors may submit written questions in advance of the conference call to [email protected] or through the webcast portal. A replay of the webcast will be available on the Company’s website at ...

GTB-3650 TriKE ®  Phase 1 trial has successfully completed Cohort 1 and Cohort 2 dosing, treating a total of four patients; following Cohort 2’s formal safety review, it has advanced into Cohort 3 and ...

Ended the quarter with $4.8 million in cash following the closing of a private placement pursuant to a securities purchase agreement with an accredited investor for aggregate gross proceeds of $4.25 ...